MSCI Inc - MSCI STOCK NEWS

MSCI Inc. (NYSE:MSCI), a prominent provider of research-based indexes, is set to announce the results of its May 2021 Semi-Annual Index Review. This review includes various MSCI Equity Indexes, such as the Global Standard and Micro Cap Indexes. Changes will be effective after May 27, 2021. The list of index additions and deletions will be available on their website shortly after 11:00 p.m. CEST on May 11, 2021, with further information for subscribers accessible immediately after the announcement.

MSCI Inc. (NYSE: MSCI) released an investor presentation on May 4, 2021, accessible on its website. The presentation is intended for use by the management team during investor meetings. MSCI specializes in providing critical decision support tools and services to the global investment community, with over 50 years of experience in research, data, and technology. The company aims to empower clients in making informed investment decisions by offering insights into key risk and return factors, thereby enhancing portfolio effectiveness.

MSCI announced a private offering of $600 million in senior unsecured notes due 2031, increasing its initial offering by $100 million. The notes will carry an interest rate of 3.625%, payable semi-annually starting November 1, 2021. Proceeds will be used for general corporate purposes, including potential stock purchases and acquisitions. The offering is intended for qualified institutional buyers and certain non-U.S. persons, with no registration under the Securities Act. MSCI highlights its robust expertise in investment decision support tools and forward-looking statements regarding potential future performance.

MSCI Inc. has announced its intention to issue $500 million in senior unsecured notes due 2031 in a private offering exempt from Securities Act registration. The offering is subject to market conditions, and if successful, the proceeds will be utilized for general corporate purposes including stock purchases, investments, and offering-related expenses. The notes are being offered only to qualified institutional buyers and certain non-U.S. persons, and they have not been registered under the Securities Act, limiting their sale in the U.S.

MSCI reported strong financial results for Q1 2021, with operating revenues of $478.4 million, a 14.8% increase year-over-year. Key highlights include diluted EPS of $2.36, up 36.4%, and adjusted EBITDA margin of 57.8%, reflecting a robust operational performance. The company demonstrated solid recurring subscription revenue growth of 10.9% and a remarkable 26.5% rise in asset-based fees. The retention rate improved to 96.3%. MSCI anticipates higher operating expenses for 2021 with guidance set for $885 to $920 million.

MSCI announced a collaboration with Royalty Pharma to enhance its thematic index suite, focusing on companies in virology and oncology. This partnership aims to design indexes that will capture innovative therapeutic treatments in the life sciences sector. Royalty Pharma will provide its expertise in medical conditions and clinical trials to assist MSCI in creating an effective classification framework. The initial indexes are set to launch later this year, with the potential to influence investment strategies targeting the evolving biotechnology field.

MSCI Inc. (NYSE: MSCI) will release its Q1 2021 financial results on April 27, 2021. The earnings release, presentation, and quarterly update will be available on its Investor Relations homepage. Senior management will discuss these results during a live event at 11:00 AM ET, accessible via their website or by phone. An archived version of the webcast will also be available shortly after. MSCI provides critical tools for investment decision-making, leveraging over 50 years of expertise to enhance portfolio management and risk analysis.